Table A6.
Surgery for Residual Masses if Residual Masses in Patient With Nonseminoma
| Surgery for Residual Masses | Treatment |
Total (N = 249) |
||||
|---|---|---|---|---|---|---|
| BEP (n = 123) |
T-BEP (n = 126) |
|||||
| No. of Patients | % | No. of Patients | % | No. of Patients | % | |
| No residual masses resected | 22 | 17.9 | 21 | 16.7 | 43 | 17.3 |
| Resection of lesions but at least one remaining | 28 | 22.8 | 31 | 24.6 | 59 | 23.7 |
| At least one lesion not completely resected | 6 | 4.9 | 3 | 2.4 | 9 | 3.6 |
| Complete resection of all masses | 60 | 48.8 | 64 | 50.8 | 124 | 49.8 |
| Unknown | 7 | 5.7 | 7 | 5.6) | 14 | 5.6 |
Abbreviations: BEP, bleomycin, etoposide, and cisplatin; T-BEP, paclitaxel–bleomycin, etoposide, and cisplatin.